New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Tumors form temporary structures to avoid immunotherapy treatments

Tumors form temporary structures to avoid immunotherapy treatments

byeLifeTumor-reactive T cells induce transient cell-in-cell structure. (A) Mean percentage of cell-in-cell tumor formations following incubation of B16F10 cells with immune cells (n=4). (B) Repr
Oncology January 22,2024
Tumors form temporary structures to avoid immunotherapy treatments

Tumors form temporary structures to avoid immunotherapy treatments

byeLifeTumor-reactive T cells induce transient cell-in-cell structure. (A) Mean percentage of cell-in-cell tumor formations following incubation of B16F10 cells with immune cells (n=4). (B) Repr
Oncology January 22,2024
Rethinking the protein inhibitor approach to cancer therapy

Rethinking the protein inhibitor approach to cancer therapy

byStony Brook UniversityTwo-step strategy for repeatable site-specific gene circuit integration.a, Network diagram of regulatory interactions and phenotypic impacts for native and ectopic
Oncology January 22,2024
Rethinking the protein inhibitor approach to cancer therapy

Rethinking the protein inhibitor approach to cancer therapy

byStony Brook UniversityTwo-step strategy for repeatable site-specific gene circuit integration.a, Network diagram of regulatory interactions and phenotypic impacts for native and ectopic
Oncology January 22,2024
Loyalty card data could help to identify ovarian cancer symptoms sooner

Loyalty card data could help to identify ovarian cancer symptoms sooner

byLancaster UniversityThe study of almost 300 women found that pain and indigestion medication purchases were higher in women who were subsequently diagnosed with ovarian cancer, compared to wom
Oncology January 22,2024
Loyalty card data could help to identify ovarian cancer symptoms sooner

Loyalty card data could help to identify ovarian cancer symptoms sooner

byLancaster UniversityThe study of almost 300 women found that pain and indigestion medication purchases were higher in women who were subsequently diagnosed with ovarian cancer, compared to wom
Oncology January 22,2024
Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer marker
Oncology January 22,2024
Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer marker
Oncology January 22,2024
Experts boost activity of potential therapeutic target in triple-negative breast cancer

Experts boost activity of potential therapeutic target in triple-negative breast cancer

by Diana Yates,University of Illinois at Urbana-ChampaignCredit: Unsplash/CC0 Public DomainLess than 20% of diagnosed breast cancers are designated "triple-negative," lacking three typ
Oncology January 22,2024
Experts boost activity of potential therapeutic target in triple-negative breast cancer

Experts boost activity of potential therapeutic target in triple-negative breast cancer

by Diana Yates,University of Illinois at Urbana-ChampaignCredit: Unsplash/CC0 Public DomainLess than 20% of diagnosed breast cancers are designated "triple-negative," lacking three typ
Oncology January 22,2024
Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainChemotherapy-induced peripheral neuropathy (CIPN)—nerve pain, tingling, or numbness in the hands or feet—is a common side effect of cer
Oncology January 22,2024
Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainChemotherapy-induced peripheral neuropathy (CIPN)—nerve pain, tingling, or numbness in the hands or feet—is a common side effect of cer
Oncology January 22,2024
Race could affect outcomes in head and neck cancers

Race could affect outcomes in head and neck cancers

by Cara Murez HealthDay ReporterBlack patients with head and neck cancers have twice the death rates of white patients, and a new study suggests race itself underlies those differences."What is u
Oncology January 22,2024
Race could affect outcomes in head and neck cancers

Race could affect outcomes in head and neck cancers

by Cara Murez HealthDay ReporterBlack patients with head and neck cancers have twice the death rates of white patients, and a new study suggests race itself underlies those differences."What is u
Oncology January 22,2024
Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

byUniversity of CambridgeCredit: Pixabay/CC0 Public DomainCambridge scientists have managed to identify and kill those breast cancer cells that evade standard treatments in a study in mice. The
Oncology January 22,2024
Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

byUniversity of CambridgeCredit: Pixabay/CC0 Public DomainCambridge scientists have managed to identify and kill those breast cancer cells that evade standard treatments in a study in mice. The
Oncology January 22,2024
Stopping a rare childhood cancer in its tracks

Stopping a rare childhood cancer in its tracks

byCold Spring Harbor LaboratoryScientists discovered targeting a protein called ETV6 can turn Ewing sarcoma cancer cells back to normal-looking and -behaving connective tissue cells, as seen abo
Oncology January 22,2024
Stopping a rare childhood cancer in its tracks

Stopping a rare childhood cancer in its tracks

byCold Spring Harbor LaboratoryScientists discovered targeting a protein called ETV6 can turn Ewing sarcoma cancer cells back to normal-looking and -behaving connective tissue cells, as seen abo
Oncology January 22,2024
Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

byDana-Farber Cancer InstituteOverall survival in the intention-to-treat population. This is the planned final analysis of overall survival in the intent-to-treat population of all randomly assi
Oncology January 22,2024
Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

byDana-Farber Cancer InstituteOverall survival in the intention-to-treat population. This is the planned final analysis of overall survival in the intent-to-treat population of all randomly assi
Oncology January 22,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com